Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 10 de 10
Filtrer
1.
J Biol Inorg Chem ; 26(4): 385-401, 2021 06.
Article de Anglais | MEDLINE | ID: mdl-33837856

RÉSUMÉ

Metal complexes based on ruthenium have established excellent activity with less toxicity and great selectivity for tumor cells. This study aims to assess the anticancer potential of ruthenium(II)/allopurinol complexes called [RuCl2(allo)2(PPh3)2] (1) and [RuCl2(allo)2(dppb)] (2), where allo means allopurinol, PPh3 is triphenylphosphine and dppb, 1,4-bis(diphenylphosphino)butane. The complexes were synthesized and characterized by elemental analysis, IR, UV-Vis and NMR spectroscopies, cyclic voltammetry, molar conductance measurements, as well as the X-ray crystallographic analysis of complex 2. The antitumor effects of compounds were determined by cytotoxic activity and cellular and molecular responses to cell death mechanisms. Complex 2 showed good antitumor profile prospects because in addition to its cytotoxicity, it causes cell cycle arrest, induction of DNA damage, morphological and biochemical alterations in the cells. Moreover, complex 2 induces cell death by p53-mediated apoptosis, caspase activation, increased Beclin-1 levels and decreased ROS levels. Therefore, complex 2 can be considered a suitable compound in antitumor treatment due to its cytotoxic mechanism.


Sujet(s)
Allopurinol/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/pharmacologie , Tumeurs mammaires de l'animal/traitement médicamenteux , Composés du ruthénium/composition chimique , Composés du ruthénium/pharmacologie , Allopurinol/composition chimique , Animaux , Liquide d'ascite/cytologie , Cycle cellulaire/effets des médicaments et des substances chimiques , Tests de migration cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Femelle , Fibroblastes , Humains , Souris , Tumeurs expérimentales/traitement médicamenteux
3.
Microvasc Res ; 101: 118-26, 2015 Sep.
Article de Anglais | MEDLINE | ID: mdl-26215931

RÉSUMÉ

Recent data has indicated that, besides its classical therapeutic indication in hyperurecemia and gout, xanthine oxidase inhibitors can be used to various forms of ischemia and other types of tissue and vascular injuries. We tested the hypothesis that allopurinol, an inhibitor of xanthine oxidase (XO), might modulate acute and/or chronic inflammatory angiogenesis induced by subcutaneous implantation of synthetic matrix in mice. C57/BL6 male mice (6-7 weeks) were implanted with polyether-polyurethane sponge discs. The animals received by oral gavage 1.0mg/kg of allopurinol for six consecutive days in two treatment regimen. In the first series of experiments, the treatment was initiated 24h post-implantation and the implants were removed at day 7 post-implantation. For the assessment of the effect of the compound on chronic inflammation, the treatment was initiated at day 8 post-implantation and the implants removed 14days post-implantation. Angiogenesis as determined by hemoglobin content, VEGF levels and number of vessels intraimplant, and inflammation (myeloperoxidase -MPO, n-acetyl-ß-d-glucosaminidase -NAG, TNF-α and CCL2 levels) were reduced by allopurinol treatment in acute phase. Similarly, the treatment inhibited nitric oxide and H2O2 production. However, fibrogenesis determined by collagen deposition and levels of TGF-ß1 increased in the implants after allopurinol treatment. In marked contrast with the effects when the treatment initiated 24h post-implantation, allopurinol increased angiogenesis and inflammation but reduced collagen and TGF-ß1 levels intra-implant, when the treatment was started during the chronic inflammatory process. The dual effects of allopurinol described here, extend its range of actions as a potential agent able to modulate the components of the fibrovascular tissue present in both physiological (healing processes) as well as in chronic fibroproliferative diseases. These modulatory effects depended on the phase at which the treatment was initiated.


Sujet(s)
Allopurinol/composition chimique , Acetylglucosaminidase/métabolisme , Animaux , Collagène/composition chimique , Oxyde de diéthyle/composition chimique , Hémoglobines/analyse , Hémoglobines/métabolisme , Peroxyde d'hydrogène/composition chimique , Inflammation , Mâle , Souris , Souris de lignée C57BL , Modèles animaux , Néovascularisation pathologique/traitement médicamenteux , Monoxyde d'azote/composition chimique , Myeloperoxidase/métabolisme , Polyuréthanes/composition chimique , Facteurs temps , Facteur de croissance transformant bêta-1/métabolisme , Facteur de nécrose tumorale alpha/métabolisme , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Xanthine oxidase/antagonistes et inhibiteurs
4.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 23(4): 65-70, out.-dez.2013.
Article de Portugais | LILACS | ID: lil-742386

RÉSUMÉ

Insuficiência cardíaca é caracterizada, dentre outrosaspectos, por vasoconstrição periférica secundária à ativaçãoneuro-hormonal e alteração da função endotelial. O endotélioregula a homeostase vascular e, nesse contexto, o óxido nítricose destaca devido sua importância quanto à promoção devasodilatação, inibição da ativação plaquetária, inibição daagregação dos monócitos ao endotélio e inibição da proliferaçãoanormal da musculatura lisa vascular, Está bem demonstradona literatura médica que, nos portadores de insuficiência cardíaca,a disfunção endotelial ocorre com frequência e, quandopresente, provoca significativo impacto prognóstico negativo.No entanto, a disfunção endotelial melhora consideravelmentecom o tratamento clínico...


Heart failure is characterized by peripheral vasoconstrictiondue to neuro hormonal activation and alteration of endothelialfunction. The endothelium regulates vascular homeostasis,nitric oxide stands out, owing its importance as promotingvasodilation, inhibition of platelet activation, aggregationinhibition of monocytes to endothelium and inhibiting theabnormal proliferation of vascular smooth muscle. It is welldemonstrated in the literature that in heart failure patients,endothelial dysfunction occurs frequently and when presentit leads to a significant negative prognostic impact, however,considerable improvement occurs when clinical treatment isapplied...


Sujet(s)
Humains , Endothélium/physiopathologie , Défaillance cardiaque , Monoxyde d'azote/composition chimique , Allopurinol/composition chimique , Exercice physique
5.
Antimicrob Agents Chemother ; 56(6): 2858-67, 2012 Jun.
Article de Anglais | MEDLINE | ID: mdl-22411610

RÉSUMÉ

An innovative liposomal formulation of meglumine antimoniate (LMA) was recently reported to promote both long-term parasite suppression and reduction of infectivity to sand flies in dogs with visceral leishmaniasis. However, 5 months after treatment, parasites were still found in the bone marrow of all treated dogs. In order to improve treatment with LMA, the present study aimed to evaluate its efficacy in combination with allopurinol. Mongrel dogs naturally infected with Leishmania infantum were treated with six doses of LMA (6.5 mg Sb/kg of body weight/dose) given at 4-day intervals, plus allopurinol (20 mg/kg/24 h per os) for 140 days. Comparison was made with groups treated with LMA, allopurinol, empty liposomes plus allopurinol, empty liposomes, and saline. Dogs remained without treatment from day 140 to 200 after the start of treatment. The drug combination promoted both clinical improvement of dogs and significant reduction in the parasitic load in bone marrow and spleen on days 140 and 200 compared to these parameters in the pretreatment period. This is in contrast with the other protocols, which did not result in significant reduction of the bone marrow parasite load on day 200. Strikingly, the combined treatment, in contrast to the other regimens, induced negative quantitative PCR (qPCR) results in the liver of 100% of the dogs. Both xenodiagnosis and skin parasite determination by qPCR indicated that the drug combination was effective in blocking the transmission of skin parasites to sand flies. Based on all of the parasitological tests performed on day 200, 50% of the animals that received the combined treatment were considered cured.


Sujet(s)
Allopurinol/composition chimique , Allopurinol/usage thérapeutique , Antiprotozoaires/usage thérapeutique , Leishmaniose viscérale/traitement médicamenteux , Liposomes/composition chimique , Méglumine/composition chimique , Méglumine/usage thérapeutique , Composés organométalliques/composition chimique , Composés organométalliques/usage thérapeutique , Animaux , Antiprotozoaires/composition chimique , Chiens , Femelle , Mâle , Antimoniate de méglumine
6.
Braz. j. pharm. sci ; 47(3): 513-523, July-Sept. 2011. graf, tab
Article de Anglais | LILACS | ID: lil-602668

RÉSUMÉ

Allopurinol is a commonly used drug in the treatment of chronic gout or hyperuricaemia associated with treatment of diuretic conditions. One of the major problems with the drug is that it is practically insoluble in water, which results in poor bioavailability after oral administration. In the present study, solid dispersions of allopurinol were prepared by solvent evaporation, kneading method, co-precipitation method, co-grinding method and closed melting methods to increase its water solubility. Hydrophilic carriers such as polyvinylpyrrolidone, polyethylene glycol 6000 were used in the ratio of 1:1, 1:2 and 1:4 (drug to carrier ratio). The aqueous solubility of allopurinol was favored by the presence of both polymers. These new formulations were characterized in the liquid state by phase solubility studies and in the solid state by differential scanning calorimetry, powder X-ray diffraction, UV and Fourier Transform Infrared spectroscopy. Solid state characterizations indicated that allopurinol was present as an amorphous material and entrapped in polymer matrix. In contrast to the very slow dissolution rate of pure allopurinol, the dispersion of the drug in the polymers considerably enhanced the dissolution rate. Solid dispersion prepared with polyvinylpyrrolidone showed highest improvement in wettability and dissolution rate of allopurinol. Mathematical modeling of in vitro dissolution data indicated the best fitting with Korsemeyer-Peppas model and the drug release kinetics primarily as Non-Fickian diffusion. Therefore, the present study showed that polyvinylpyrrolidone and polyethylene glycol 6000 have a significant solubilizing effect on allopurinol.


Alopurinol é fármaco comumente utilizado no tratamento de gota crônica ou hiperuricemia associada com o tratamento em condições diuréticas. Um dos maiores problemas com o fármaco é que este é praticamente insolúvel em água, o que resulta em baixa biodisponibilidade na administração oral. No presente estudo, dispersões sólidas de alopurinol foram preparadas pela evaporação do solvente, pelos métodos de amassamento, de coprecipitação, de comoagem e fusão fechada para aumentar sua solubilidade em água. Transportadores hidrofílicos, como polivinilpirrolidona, polietilenoglicol 6000 foram utilizados nas proporções de 1:1. 1:2 e 1:4 (fármaco: transportador). A solubilidade aquosa do alopurinol foi favorecida pela presença de ambos os polímeros. Estas novas formulações forma caracterizadas no estado líquido pelos estudos de solubilidade de fase e no estado sólido pela calorimetria diferencial de varredura, difração de Raio-X, espectroscopia de UV e de IV com transformada de Fourier. As caracterizações do estado sólido indicaram que o alopurinol estava presente como material amorfo e embebido em matriz polimérica. Ao contrário da velocidade de dissolução lenta do alopurinol puro, a dispersão do fármaco nos polímeros aumentou consideravelmente a taxa de dissolução. A dispersão sólida preparada com polivinilpirrolidona mostrou as maiores melhorias na molhabilidade e taxa de dissolução do alopurinol. A modelagem matemática dos dados da dissolução in vitro indicou o melhor ajuste ao modelo de Korsemeyer-Peppas e a cinética de liberação do fármaco primariamente como difusão não-Fickiana. Assim, o presente estudo mostrou que a polivinilpirrolidona e o polietilenoglicol 6000 têm efeito significativo na solubilização do alopurinol.


Sujet(s)
Allopurinol/analyse , Allopurinol/pharmacocinétique , Allopurinol/composition chimique , Cétomacrogol/pharmacocinétique , Solubilité , Solides Dissous/méthodes
7.
Free Radic Res ; 42(6): 593-601, 2008 Jun.
Article de Anglais | MEDLINE | ID: mdl-18569017

RÉSUMÉ

Several studies have suggested that vitamin A (retinol, ROH) presents pro-oxidant properties in biological systems. Recent studies point out that xantine oxidase, a ROS-generating enzyme, catalyses ROH oxidation to RA in vitro. These works stimulated the authors to investigate whether xanthine oxidase could be involved on the ROH pro-oxidative effects reported in cultured Sertoli cells. In vitro, it was demonstrate that xanthine oxidase generates superoxide in the presence of ROH as assessed by superoxide mediated-NBT reduction. Superoxide production is potentiated in the presence of NADH and inhibited by allopurinol. In Sertoli cells, ROH treatment increased xanthine oxidase activity and inhibition of the enzyme with allopurinol attenuated ROH-induced ROS production, protein damage and cytotoxicity. Moreover, inhibition of ROH oxidation to RA by retinaldehyde dehydrogenase inhibitor potentiated both xanthine oxidase-dependent ROS production and cell damage in ROH-treated cells. The data show that xanthine oxidase may play a role on vitamin A pro-oxidant effects.


Sujet(s)
Oxydants/métabolisme , Espèces réactives de l'oxygène/métabolisme , Cellules de Sertoli/cytologie , Rétinol/métabolisme , Xanthine oxidase/métabolisme , Allopurinol/composition chimique , Animaux , Mâle , Modèles biologiques , NAD/métabolisme , Rats , Cellules de Sertoli/métabolisme , Testicule , Facteurs temps , Acide urique/composition chimique
8.
Ann Hepatol ; 1(3): 140-6, 2002.
Article de Anglais | MEDLINE | ID: mdl-15280813

RÉSUMÉ

We examined how different media composition of rewarming solutions affected ammonium detoxification function, urea synthesis and the viability of hepatocytes after 72 hs of cold storage in UW solution. Freshly isolated rat hepatocytes were incubated at 37 C in a cell culture medium (MEM-E) with 3 mM glycine, 5 mM fructose and 2.5 mM adenosine (group 1) and in Krebs-Heinseleit buffer with 3 mM glycine, 5 mM fructose, 2 mM ornithine, 10 mM lactate and adenosine, that was used in two different concentrations: 2.5 mM (group 2) and 10 mM (group 3). We found that freshly isolated cells produced ammonium in group 1 and 2 but the cells were able to diminish ammonium extracellular concentration in group 3. Urea synthesis and ammonium extracellular concentration in group 1 was higher than in group 2. As a result of this observations, we used the Krebs-Heinseleit solution with addition of 10 mM adenosine to determinate the effect of hypothermic preservation on ammonium detoxification and urea synthesis ability of cells. In conclusion the addition of 2.5 mM adenosine into the rewarming medium interfered with the detection of ammonium detoxification of hepatic cells.


Sujet(s)
Adénosine/composition chimique , Allopurinol/composition chimique , Ammoniac/pharmacocinétique , Glutathion/composition chimique , Hépatocytes/métabolisme , Température élevée , Insuline/composition chimique , Solution conservation organe/composition chimique , Raffinose/composition chimique , Animaux , Survie cellulaire , Mâle , Rats , Rat Wistar , Urée/métabolisme
9.
Arch Med Res ; 32(4): 296-9, 2001.
Article de Anglais | MEDLINE | ID: mdl-11440787

RÉSUMÉ

BACKGROUND: Ischemia-reperfusion injury during open heart surgery related to unsuccessful myocardial protection may increase morbidity or mortality. We analyze the clinical outcome after cardiac surgery with a cardioplegic solution based on intracellular components added with histidine-ketoglutarate-tryptophan. METHODS: Thirty patients programmed for elective open heart surgery were randomized into two groups. In group I (n = 15), myocardial protection was carried out with Bretschenider solution (HTK), and in group II (n = 15) with conventional crystalloid cardioplegia. The incidence of arrhythmias, inotropic support requirement, and length-of-stay in the intensive care unit were evaluated. RESULTS: During reperfusion, there was no difference in incidence of arrhythmias; however, in the postoperative period group I had a lower incidence of arrhythmias (p = 0.001). Inotropic support (p = 0.003) and length-of-stay in the intensive care unit (p = 0.037) were lower in group I. There were no deaths in either group. CONCLUSIONS: It was concluded that myocardial protection with Bretschneider solution effectively decreases incidence of arrhythmias, inotropic support, and length-of-stay in the intensive care unit.


Sujet(s)
Solutions cardioplégiques/usage thérapeutique , Glucose/usage thérapeutique , Arrêt cardiaque provoqué , Mannitol/usage thérapeutique , Solution conservation organe , Chlorure de potassium/usage thérapeutique , Procaïne/usage thérapeutique , Adénosine/composition chimique , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Allopurinol/composition chimique , Troubles du rythme cardiaque/épidémiologie , Troubles du rythme cardiaque/prévention et contrôle , Hydrogénocarbonates/composition chimique , Chlorure de calcium/composition chimique , Solutions cardioplégiques/effets indésirables , Solutions cardioplégiques/composition chimique , Cardiotoniques/administration et posologie , Cardiotoniques/usage thérapeutique , Enfant , Enfant d'âge préscolaire , Pontage aortocoronarien , Interventions chirurgicales non urgentes , Femelle , Glucose/effets indésirables , Glucose/composition chimique , Glutathion/composition chimique , Arrêt cardiaque provoqué/effets indésirables , Cardiopathies congénitales/chirurgie , Implantation de valve prothétique cardiaque , Humains , Insuline/composition chimique , Durée du séjour , Magnésium/composition chimique , Mâle , Mannitol/effets indésirables , Mannitol/composition chimique , Adulte d'âge moyen , Lésion de reperfusion myocardique/prévention et contrôle , Complications postopératoires/épidémiologie , Complications postopératoires/prévention et contrôle , Chlorure de potassium/effets indésirables , Chlorure de potassium/composition chimique , Procaïne/effets indésirables , Procaïne/composition chimique , Études prospectives , Raffinose/composition chimique , Risque , Chlorure de sodium/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE